A Retrospective Cohort Study of Extended Dupilumab Dosing in Atopic Dermatitis: Assessing the Impact on Disease Severity and Understanding Characteristics Linked to Successful Dose Extension
{{output}}
Dupilumab is effective for moderate-to-severe atopic dermatitis, but optimal long-term dosing is unclear. In this single-centre retrospective study, 49 patients underwent dose extension to 300 mg Q3W or 300 mg Q4W, with EASI scores remaining low and stable ove... ...
